Anavex Life Sciences (AVXL) Stock Price, News & Analysis

Company Overview

Anavex Life Sciences Corp. (NASDAQ: AVXL) is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative and neurodevelopmental disorders. The company’s research centers on small-molecule treatments intended to address disease mechanisms associated with conditions affecting the central nervous system.

Anavex’s lead investigational product is blarcamesine, also known as ANAVEX2-73, an orally administered compound being studied in disorders including Alzheimer’s disease, Parkinson’s disease dementia and Rett syndrome. The company has also evaluated other pipeline candidates, including ANAVEX3-71, for potential use in neurodegenerative diseases.

Founded in 2004, Anavex conducts clinical development activities through research and trials involving participants in multiple geographic regions. The company is headquartered in New York and is led by Christopher U. Missling, Ph.D., who serves as president and chief executive officer.

Key Stats

• Today's Range: $1.72 to $1.88
• 50-Day Range: $1.82 to $3.56
• 52-Week Range: $1.72 to $10.38
• Volume: 1.99 million shs
• Average Volume: 871,033 shs
• Market Capitalization: $168.71 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.33
• Consensus Rating: Hold

Anavex Life Sciences Stock Analysis - MarketRank™

Anavex Life Sciences scored higher than 27% of companies evaluated by MarketBeat, and ranked 760th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Anavex Life Sciences has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Anavex Life Sciences has a consensus price target of $21.33, representing about 1,072.2% upside from its current price of $1.82.

Amount of Analyst Coverage

Anavex Life Sciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Anavex Life Sciences are expected to decrease in the coming year, from ($0.33) to ($0.55) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Anavex Life Sciences is -12.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Anavex Life Sciences is -12.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Anavex Life Sciences has a P/B Ratio of 1.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.45% of the float of Anavex Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

Anavex Life Sciences has a short interest ratio ("days to cover") of 25.13, which indicates bearish sentiment.

Change versus previous month

Short interest in Anavex Life Sciences has recently increased by 3.13%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Anavex Life Sciences does not currently pay a dividend.

Dividend Growth

Anavex Life Sciences does not have a long track record of dividend growth.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.04

News Sentiment

Anavex Life Sciences has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 25 news articles for Anavex Life Sciences this week, compared to 5 articles on an average week.

Search Interest

Only 1 people have searched for AVXL on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Anavex Life Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Anavex Life Sciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.40% of the stock of Anavex Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

31.55% of the stock of Anavex Life Sciences is held by institutions.

Company Calendar

• Last Earnings: 8/25/2026
• Today: 10/03/2026
• Next Earnings (Estimated): 11/24/2026
• Fiscal Year End: 9/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:AVXL
• CIK: 1314052
• Web: www.anavex.com
• Phone: (844) 689-3939
• Fax: N/A
• Employees: 34
• Year Founded: 2006

Price Target and Rating

• Average Price Target for Anavex Life Sciences: $21.33
• High Price Target: $24.00
• Low Price Target: $20.00
• Potential Upside/Downside: +1,072.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$46.38 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -11.43%
• Return on Assets: -10.72%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.62
• Quick Ratio: 15.62

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.10 per share
• Price / Book: 1.65

Miscellaneous

• Outstanding Shares: 92,697,000
• Free Float: 82,130,000
• Market Cap: $168.71 million
• Optionable: Optionable
• Beta: 1.17